Single high-dose buprenorphine for opioid craving during withdrawal
Authors:
Open Access
- 10 December 2018
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 19 (1) , 675
Abstract
Opioid use disorder is one of the most prevalent addiction problems worldwide. Buprenorphine is used as a medication to treat this disorder, but in countries where buprenorphine is unavailable in combination with naloxone, diversion can be a problem if the medication is given outside a hospital setting. The objective of this research is to evaluate the effect of a single, high dose of buprenorphine on craving in opioid-dependent patients over 5 days of abstinence from use of other opioids. The primary goal was to determine the safety and efficacy of buprenorphine during withdrawal in a hospital setting. Ninety men who used opium, heroin, or prescribed opioids and met DSM-5 criteria for opioid use disorder (severe form) were randomized to three groups (n = 30 per group) to receive a single, sublingual dose of buprenorphine (32, 64, or 96 mg). The study was conducted in an inpatient psychiatric ward, with appropriate precautions and monitoring of respiratory and cardiovascular measures. Buprenorphine was administered when the patients were in moderate opiate withdrawal, as indicated by the presence of four to five symptoms. A structured clinical interview was conducted, and urine toxicology testing was performed at baseline. Self-reports of craving were obtained at baseline and on each of the 5 days after buprenorphine administration. Craving decreased from baseline in each of the three groups (p < 0.0001), with a significant interaction between group and time (p < 0.038), indicating that groups with higher doses of buprenorphine had greater reduction. A single, high dose of buprenorphine can reduce craving during opioid withdrawal; additional studies with follow-up are warranted to evaluate safety.Keywords
Funding Information
- Shiraz University of Medical Sciences (IRCT2016071325160N4)
This publication has 27 references indexed in Scilit:
- Crystal structure of the µ-opioid receptor bound to a morphinan antagonistNature, 2012
- Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts?Annals of General Psychiatry, 2011
- Suicidality and divalproex sodium: analysis of controlled studies in multiple indicationsAnnals of General Psychiatry, 2011
- Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: A retrospective studyProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2006
- The rise of the modern addict.American Journal of Public Health, 1995
- Substitution Pharmacotherapies for Opioid Addiction: From Methadone to LAAM and BuprenorphineJournal of Psychoactive Drugs, 1994
- κ antagonist properties of buprenorphine in the shock titration procedureEuropean Journal of Pharmacology, 1988
- Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and miceEuropean Journal of Pharmacology, 1988
- BuprenorphineDrug and Alcohol Dependence, 1985
- Intrinsic ActivityJournal of Cardiovascular Pharmacology, 1983